These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26273714)

  • 41. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 42. Cholesterol limits lose their lustre.
    Ledford H
    Nature; 2013 Feb; 494(7438):410-1. PubMed ID: 23446392
    [No Abstract]   [Full Text] [Related]  

  • 43. PCSK9 inhibitors on the way.
    Patel KR
    Manag Care; 2014 Nov; 23(11):43. PubMed ID: 25939173
    [No Abstract]   [Full Text] [Related]  

  • 44. [Hypercholesterolemia: Monoclonal antibodies safe and effective].
    Windler E
    Dtsch Med Wochenschr; 2015 May; 140(11):785-6. PubMed ID: 26080713
    [No Abstract]   [Full Text] [Related]  

  • 45. Targeting PCSK9 for therapeutic gains.
    Shapiro MD; Fazio S; Tavori H
    Curr Atheroscler Rep; 2015 Apr; 17(4):499. PubMed ID: 25712137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.
    Budha NR; Leabman M; Jin JY; Wada DR; Baruch A; Peng K; Tingley WG; Davis JD
    AAPS J; 2015 Jul; 17(4):881-90. PubMed ID: 25823668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
    Yoon CH; Watson K
    Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
    Pokharel Y; Virani SS; Ballantyne CM
    Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PCSK9 Inhibitors May Show Benefits of Ultra-Low LDL Levels.
    Reinke T
    Manag Care; 2015 Aug; 24(8):13-4. PubMed ID: 26399135
    [No Abstract]   [Full Text] [Related]  

  • 56. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.
    Shantha GP; Robinson JG
    Clin Pharmacol Ther; 2016 Jan; 99(1):59-71. PubMed ID: 26492546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):140-1. PubMed ID: 26445204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trial watch: PCSK9 antibody reduces LDL cholesterol.
    Crunkhorn S
    Nat Rev Drug Discov; 2012 Jan; 11(1):11. PubMed ID: 22212668
    [No Abstract]   [Full Text] [Related]  

  • 60. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.